Trial Profile
Double-blind, Placebo-controlled, Randomized Phase II-study Investigating the Efficacy of Bevacizumab for Symptom Control in Patients With Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Gastrointestinal cancer; Malignant ascites
- Focus Therapeutic Use
- 14 Jun 2016 Results published in the European Journal of Cancer
- 12 Apr 2015 Status changed from discontinued to completed as reported by ClinicalTrials.gov record.
- 25 Apr 2014 Planned End Date changed from 1 Oct 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.